Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Psycho-Oncology|February 27, 2010
Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partnersAlex Molassiotis, Barbara Wilson, Susan Blair, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 10, 2009
Living with multiple myeloma: experiences of patients and their informal caregiversAlex Molassiotis, Barbara Wilson, Susan Blair, et al.
British Journal of Haematology|August 22, 2003
Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantationHannah Cullup, Anne M Dickinson, James Cavet, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 28, 2003
Predicting outcome in hematological stem cell transplantationAnne M Dickinson, James Cavet, Hannah Cullup, et al.
The Journal of Experimental Medicine|January 5, 2006
The fate of human Langerhans cells in hematopoietic stem cell transplantationMatthew P Collin, Derek N J Hart, Graham H Jackson, et al.
The Patient|March 5, 2015
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of SiltuximabFrits van Rhee, Margaret Rothman, Kai Fai Ho, et al.
British Journal of Haematology|April 21, 2015
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trialSteve Schey, Sarah R Brown, Avie-Lee Tillotson, et al.
The Lancet. Oncology|April 22, 2011
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyPhilippe Moreau, Halyna Pylypenko, Sebastian Grosicki, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
The Lancet. Oncology|July 22, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialFrits van Rhee, Raymond S Wong, Nikhil Munshi, et al.
Pageof 2